Extracted from the Phyllanthus engleri tree, englerin A kills the cancer cells by increasing their calcium concentration
Nature holds many compounds in store that are of great value to medical research. Recently, for example, scientists discovered that a substance contained in an African shrub kills cancer cells in the kidney.
Together with colleagues from Berlin and Leeds, researchers from the Max Planck Institute of Molecular Physiology in Dortmund discovered that the molecule known as englerin A significantly increases the concentration of calcium in cells, causing the cancer cells to die.
Englerin A only activates the calcium channels of renal cancer cells, but not those of healthy cells. In cooperation with the Lead Discovery Center in Dortmund, the scientists now want to find out whether englerin A could potentially be used as an innovative drug to treat renal cancer in the future.
In its native habitat in southern Africa, Phyllanthus engleri has long been known to have medicinal properties. The shrub or small tree, which was formerly classified as belonging to the spurge family, is most commonly found in the dry savannahs of Tanzania, Zambia, Malawi, Zimbabwe, Mozambique and South Africa.
In Tanzania, for example, the plant’s roots are used to treat epilepsy, and chewing the leaves and fruits is said to alleviate coughs and stomach aches. A decoction made from the roots is even said to be effective against bilharziosis and gonorrhoea. At the same time, the plant also contains strong toxins that can cause lethal poisoning.
In 2009, American scientists isolated more than 30 substances found in Phyllanthus engleri and tested their efficacy on cancer cells. They discovered that a specific type of compound taken from the bark of the tree – a variant known as (–)-englerin A – is particularly effective against renal cancer cells and some other forms of cancer.
That same year, the group led by Mathias Christmann, who now conducts research at the Freie Universität Berlin, synthesised this complex compound. The precursor they used is the primary constituent in the essential oil of catnip (Nepeta cataria): nepetalactone – a substance that causes cats to lapse into a state of ecstasy. Nepetalactone is therefore a renewable raw material extracted from a plant that is more readily available than Phyllantus engleri. This is decisive for the further use of englerin A, as it means that larger amounts of the substance can be produced.
However, exactly how englerin A kills cancer cells remained a mystery. Until recently, it was believed that englerin A might target a variant of the enzyme protein kinase C. The Max Planck scientists have now discovered though that cells that respond to englerin A particularly well do not contain this type of enzyme at all. Instead, the researchers focused on a family of calcium channels known as TRPCs (canonical transient receptor potential channels), which are found in the membranes of renal cells.
Different renal cancer cells form different numbers of these channels. The measurements showed that adding englerin A causes the calcium concentration inside these cells to rise so significantly that the cells die within a few minutes.
“We studied cancer cells that produce a lot of TRPC4. These cells are particularly sensitive to englerin A. In cells that do not produce any TRPC4 or only produce normal amounts, the calcium levels do not rise as much. Therefore, these cells don’t die,” explains Slava Ziegler from the Max Planck Institute of Molecular Physiology. However, the researchers still do not know whether the overproduction of TRPCs is the sole cause of the dying off of the cancer cells.
Englerin A thus acts specifically on cancer cells in the kidney. “This property gives the substance a major advantage over other anti-cancer drugs, because it means the side effects afflicting healthy cells could possibly be prevented,” says Herbert Waldmann from the Max Planck Institute in Dortmund, where, among other topics, he conducts research into the use of naturally occurring substances in the development of active agents.
Together with the Lead Discovery Center in Dortmund, the researchers now want to determine whether englerin A is suitable as an anti-cancer drug. The Center, which was founded by the Max Planck Society, helps bring potential active agents from basic research to clinical trial. “Englerin A is a prime example of an active substance that harbours great potential, but also a significant risk. In the current phase there would be hardly any commercial partners willing to provide the funding for further studies. The Lead Discovery Center can bridge this gap between basic research and medicine,” says Waldmann.
Yasemin Akbulut, Hannah J. Gaunt, Katsuhiko Muraki, Melanie J. Ludlow, Mohamed S. Amer, Alexander Bruns, Naveen S. Vasudev, Lea Radtke, Matthieu Willot, Sven Hahn, Tobias Seitz, Slava Ziegler, Mathias Christmann, David J Beech, and Herbert Waldmann
(-)-Englerin A: A Potent and Selective Activator of TRPC4 and TRPC5 Calcium Channels
Angewandte Chemie, 17 March 2015
Dr. Peter Herter | Max Planck Institute of Molecular Physiology, Dortmund
Oxygen can wake up dormant bacteria for antibiotic attacks
08.12.2016 | Penn State
NTU scientists build new ultrasound device using 3-D printing technology
07.12.2016 | Nanyang Technological University
In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.
Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...
Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
08.12.2016 | Life Sciences
08.12.2016 | Physics and Astronomy
08.12.2016 | Materials Sciences